Maxigen Biotech Inc.

TWSE:1783 Voorraadrapport

Marktkapitalisatie: NT$3.7b

Maxigen Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Maxigen Biotech has a total shareholder equity of NT$1.3B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.6B and NT$236.5M respectively. Maxigen Biotech's EBIT is NT$124.9M making its interest coverage ratio -5.1. It has cash and short-term investments of NT$520.8M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

NT$0

Schuld

Rente dekkingsratio-5.1x
ContantNT$520.79m
AandelenNT$1.33b
Totaal verplichtingenNT$236.54m
Totaal activaNT$1.57b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Analyse van de financiële positie

Kortlopende schulden: 1783's short term assets (NT$728.6M) exceed its short term liabilities (NT$235.6M).

Langlopende schulden: 1783's short term assets (NT$728.6M) exceed its long term liabilities (NT$942.0K).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1783 is debt free.

Schuld verminderen: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 26%.

Schuldendekking: 1783 has no debt, therefore it does not need to be covered by operating cash flow.

Rentedekking: 1783 has no debt, therefore coverage of interest payments is not a concern.

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y